EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease

Renato D Lopes, Edimar Alcides Bocchi, Luis Eduardo Echeverría, Caroline Demacq, Pedro Gabriel Melo de Barros E Silva, Lilian Mazza Barbosa, Lucas Damiani, Sarfaraz Sayyed, Liandra A F Yoshida, Remo Holanda M Furtado, Carlos A Morillo, Ruben Kevorkian und 41 weitere

JAMA · 2026

DOI: 10.1001/jama.2025.19808 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift JAMA, 2026. Verfasst von Renato D Lopes und 52 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute (DCRI), Duke Health, Durham, North Carolina. Hauptthemen laut MEDLINE: Aminobutyrates, Biphenyl Compounds, Chagas Cardiomyopathy, Enalapril. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The efficacy and safety of guideline-recommended treatments for heart failure (HF) are uncertain in patients with Chagas disease.

Objective

To evaluate the efficacy and safety of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan in patients with HF with reduced ejection fraction due to Chagas disease. Design, Setting, and Participants From December 10, 2019, through September 13, 2023, patients with HF, confirmed diagnosis of Chagas disease, left ventricular ejection fraction of 40% or less, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) of 600 pg/mL or greater (or B-type natriuretic peptide [BNP] ≥150 pg/mL) or 400 pg/mL or greater (or BNP ≥100 pg/mL) if hospitalized for HF within the previous 12 months were screened at 83 sites in Argentina, Brazil, Colombia, and Mexico. Statistical analysis was conducted between May and July 2025.

Interventions

Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or enalapril (target dose, 10 mg twice daily), in addition to standard therapy. Main Outcomes and Measures The primary end point was a hierarchical composite outcome tested, in order, of death from cardiovascular causes, hospitalization for HF, or relative change in NT-proBNP from baseline to 12 weeks. The primary analysis was done using a win ratio approach.

Results

Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female). Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group. A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF. Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (−54.3% to −0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (−31.9% to 37.5%) decrease (7.2% wins). The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P < .001) for sacubitril/valsartan compared with enalapril. Conclusions and Relevance In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group. Trial Registration ClinicalTrials.gov Identifier: NCT04023227

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesBiphenyl CompoundsChagas CardiomyopathyEnalaprilHeart FailureValsartanAgedFemaleHumansMaleMiddle AgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsDrug CombinationsFollow-Up StudiesHospitalizationNatriuretic Peptide, BrainNeprilysinPeptide FragmentsStroke Volume

Substanzen

AminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDrug CombinationsEnalaprilNatriuretic Peptide, BrainNeprilysinPeptide Fragmentspro-brain natriuretic peptide (1-76)

Autor:innen und Institutionen

  • Duke Clinical Research Institute (DCRI), Duke Health, Durham, North Carolina.
  • Brazilian Clinical Research Institute (BCRI), São Paulo.
  • Instituto do Coração (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
  • Novartis Biociencias SA, São Paulo, Brazil.
  • Novartis Healthcare Pvt Ltd, Hyderabad, India.

Zitieren

APA

Lopes, R. D., Bocchi, E. A., Echeverría, L. E., Demacq, C., de Barros E Silva, P. G. M., Barbosa, L. M., Damiani, L., Sayyed, S., Yoshida, L. A. F., Furtado, R. H. M., Morillo, C. A., Kevorkian, R., Ramires, F., Bahit, M. C., Magaña, A., Chávez-Mendoza, A., Miguel da Silva, A. H., Coelho da Silva, A., Freitas, A. F., …, & Prevention and Reduction of Adverse Outcomes in Chagasic Heart Failure Trial Evaluation (PARACHUTE-HF) Investigators (2026). Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease. JAMA. https://doi.org/10.1001/jama.2025.19808

Vancouver

Lopes RD, Bocchi EA, Echeverría LE, Demacq C, de Barros E Silva PGM, Barbosa LM, et al. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease. JAMA. 2026. doi:10.1001/jama.2025.19808

BibTeX
@article{Lopes2026,
  author = {Lopes, Renato D and Bocchi, Edimar Alcides and Echeverría, Luis Eduardo and Demacq, Caroline and de Barros E Silva, Pedro Gabriel Melo and Barbosa, Lilian Mazza and Damiani, Lucas and Sayyed, Sarfaraz and Yoshida, Liandra A F and Furtado, Remo Holanda M and Morillo, Carlos A and Kevorkian, Ruben and Ramires, Felix and Bahit, M Cecilia and Magaña, Antonio and Chávez-Mendoza, Adolfo and Miguel da Silva, Adegil Henrique and Coelho da Silva, Aguinaldo and Freitas, Aguinaldo F and Romano, Alfredo Alejandro and Parneix, Anne and Segura, Armando and França, Cesar Cassio Broilo and Botta, Cristian Edgardo and de Barros, Edileide and Perna, Eduardo Roque and Montenegro, Eleonora and Quiroz Diaz, Franklin Roberto and Feitosa-Filho, Gilson Soares and Severini, Graciela Viviana and Molina, Israel and Miranda, Jacqueline Dos Santos Sampaio and Sala, Jorgelina and Kerr Saraiva, José Francisco and Carbajales, Justo and Maia, Lilia Nigro and Santana Passos, Luiz Carlos and Simões, Marcus Vinicius and Moreira, Maria da Consolação V and Nunes, Maria Carmo P and Hernandes, Mauro Esteves and Hominal, Miguel and Zarandon, Raquel Saa and Leon de la Fuente, Ricardo and Aras, Roque and Bazan, Silméia Garcia Zanati and Luiz da Silva, Telêmaco and Madrini, Vagner and de Oliveira, Wilson Alves and Saporito, Wladmir Faustino and Gimpelewicz, Claudio and McMurray, John J V and Prevention and Reduction of Adverse Outcomes in Chagasic Heart Failure Trial Evaluation (PARACHUTE-HF) Investigators, Prevention and Reduction of Adverse Outcomes in Chagasic Heart Failure Trial Evaluation (PARACHUTE-HF) Investigators},
  title = {Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2025.19808}
}
Kostenlos starten →